Haemonetics completes acquisition of OpSens Inc.
by CM Staff
Haemonetics Corporation is a global provider of blood and plasma supplies and services, and acquires the Cdn. medical device manufacturer to bolster its lineup.
QUÉBEC CITY — OpSens Inc., a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, announces the successful completion of the previously announced acquisition by Haemonetics Corporation of all of the issued and outstanding common shares in the capital of OpSens for $2.90 in cash per Share, pursuant to a statutory plan of arrangement under the Business Corporations Act.
Consideration for the purchased Shares has been remitted to TSX Trust Company, as depositary under the Arrangement, and will be paid to former shareholders of OpSens as soon as reasonably practicable after the date hereof (or, in the case of registered shareholders, as soon as reasonably practicable after a properly completed and signed letter of transmittal is received by the depositary together with the share certificate(s) or DRS advice(s) representing Shares formerly held by them, if applicable).
OpSens focuses mainly on cardiology and the company offers an optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide low drift and better lesions access.
OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.
